» Articles » PMID: 10984531

Sequencing of 3-O Sulfate Containing Heparin Decasaccharides with a Partial Antithrombin III Binding Site

Overview
Specialty Science
Date 2000 Sep 14
PMID 10984531
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Heparin- and heparan sulfate-like glycosaminoglycans (HLGAGs) represent an important class of molecules that interact with and modulate the activity of growth factors, enzymes, and morphogens. Of the many biological functions for this class of molecules, one of its most important functions is its interaction with antithrombin III (AT-III). AT-III binding to a specific heparin pentasaccharide sequence, containing an unusual 3-O sulfate on a N-sulfated, 6-O sulfated glucosamine, increases 1,000-fold AT-III's ability to inhibit specific proteases in the coagulation cascade. In this manner, HLGAGs play an important biological and pharmacological role in the modulation of blood clotting. Recently, a sequencing methodology was developed to further structure-function relationships of this important class of molecules. This methodology combines a property-encoded nomenclature scheme to handle the large information content (properties) of HLGAGs, with matrix-assisted laser desorption ionization MS and enzymatic and chemical degradation as experimental constraints to rapidly sequence picomole quantities of HLGAG oligosaccharides. Using the above property-encoded nomenclature-matrix-assisted laser desorption ionization approach, we found that the sequence of the decasaccharide used in this study is DeltaU(2S)H(NS,6S)I(2S)H(NS, 6S)I(2S)H(NS,6S)IH(NAc,6S)GH(NS,3S,6S) (+/-DDD4-7). We confirmed our results by using integral glycan sequencing and one-dimensional proton NMR. Furthermore, we show that this approach is flexible and is able to derive sequence information on an oligosaccharide mixture. Thus, this methodology will make possible both the analysis of other unusual sequences in HLGAGs with important biological activity as well as provide the basis for the structural analysis of these pharamacologically important group of heparin/heparan sulfates.

Citing Articles

Mass Spectrometry for the Analysis of Highly Charged Sulfated Carbohydrates.

Chi L, Amster J, Linhardt R Curr Anal Chem. 2022; 1(3):223-240.

PMID: 35664288 PMC: 9162141. DOI: 10.2174/157341105774573929.


Informatics Ecosystems to Advance the Biology of Glycans.

Frey L Methods Mol Biol. 2021; 2303:655-673.

PMID: 34626414 DOI: 10.1007/978-1-0716-1398-6_50.


Soluble Heparin and Heparan Sulfate Glycosaminoglycans Interfere with Sonic Hedgehog Solubilization and Receptor Binding.

Manikowski D, Jakobs P, Jboor H, Grobe K Molecules. 2019; 24(8).

PMID: 31018591 PMC: 6526471. DOI: 10.3390/molecules24081607.


From Farm to Pharma: An Overview of Industrial Heparin Manufacturing Methods.

van der Meer J, Kellenbach E, van den Bos L Molecules. 2017; 22(6).

PMID: 28635655 PMC: 6152658. DOI: 10.3390/molecules22061025.


Implementation of infrared and Raman modalities for glycosaminoglycan characterization in complex systems.

Mohamed H, Untereiner V, Sockalingum G, Brezillon S Glycoconj J. 2016; 34(3):309-323.

PMID: 27928742 PMC: 5487820. DOI: 10.1007/s10719-016-9743-6.


References
1.
Sasaki T, Larsson H, Kreuger J, Salmivirta M, Claesson-Welsh L, Lindahl U . Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J. 1999; 18(22):6240-8. PMC: 1171687. DOI: 10.1093/emboj/18.22.6240. View

2.
McLaurin J, Franklin T, Zhang X, Deng J, Fraser P . Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth. Eur J Biochem. 1999; 266(3):1101-10. DOI: 10.1046/j.1432-1327.1999.00957.x. View

3.
Shriver Z, Sundaram M, Venkataraman G, Fareed J, Linhardt R, Biemann K . Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin. Proc Natl Acad Sci U S A. 2000; 97(19):10365-70. PMC: 27030. DOI: 10.1073/pnas.97.19.10365. View

4.
Linhardt R, Turnbull J, Wang H, Loganathan D, Gallagher J . Examination of the substrate specificity of heparin and heparan sulfate lyases. Biochemistry. 1990; 29(10):2611-7. DOI: 10.1021/bi00462a026. View

5.
Sasisekharan R, Moses M, Nugent M, Cooney C, Langer R . Heparinase inhibits neovascularization. Proc Natl Acad Sci U S A. 1994; 91(4):1524-8. PMC: 43192. DOI: 10.1073/pnas.91.4.1524. View